Fierce BioTech

DECEMBER 22, 2023

This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. This white paper explains how Resilience utilizes a Stage-Gate approach to technology transfer and biomanufacturing. Download now. Resilience US, Inc.

Research 52

Research 52

Alta Sciences

JULY 23, 2024

Whole Genome Sequencing, Proteomics, and Function Characterization of the Sinclair Nanopig™ for (Bio)Pharmaceuticals Safety Assessment tchichekian Tue, 07/23/2024 - 12:14 Publication White paper_Sinclair Nanopig Data_v3.pdf pdf Tags Preclinical Research URL [link] Category White Paper Weight 5

Pharmaceuticals 40

Pharmaceuticals Research 40

Alta Sciences

OCTOBER 28, 2024

White Paper: Whole Genome Sequencing, Proteomics, and Function Characterization of the Sinclair Nanopig™ Discover how the Sinclair Nanopig™ is transforming nonclinical safety assessments. Read the white paper. Watch it now. Read the eBook.

Science 52

Science Clinical Trials Trials FDA 52

Fierce BioTech

NOVEMBER 13, 2023

Download this White Paper today to learn more. jpg Tue, 11/14/2023 - 08:00 Research Research Landing Page Url [link] Byline Sponsored by: Lonza cbroadwell Mon, 11/13/2023 - 15:53 Lonza Resource Type Whitepaper F1001991_DRUCK©christianpfammatter2.jpg

Research 52

Research 52

Conversations in Drug Development Trends

MARCH 12, 2024

For a more in-depth look at biomarkers, check out our white paper. Based on previous studies, a single marker may be insufficient, and therefore, research points to the need for a “composite biomarker” made up of multiple markers meaningfully combined to inform the current disease state.

Clinical Trials 72

Clinical Trials Immune Response Trials Disease 72

Fierce BioTech

JULY 28, 2023

jsabatino Fri, 07/28/2023 - 11:29 In this white paper, we look at the past, present and future of antibodies as therapies, explaining how the modality became a key pillar of the biopharma industry—and looking forward to the methods and technologies that could unleash its full potential in the years to come. Download here!

Therapies 52

Therapies Drug Development Research Drugs 52

The Pharma Data

FEBRUARY 5, 2021

With the digitalization process, data has become the center of both traditional and research-intensive industries. In this white paper, H. Download the white paper to understand: The different types of data within an organization, and the challenges they pose. Oberkampf, C.

Production 52

Production Marketing Research 52

PPD

NOVEMBER 18, 2024

There are many nuances to ensuring that the RI gathered and monitored is as effective as possible (as discussed in our recent white paper on the topic). Download our white paper The post Leveraging FSP Solutions and Expertise to Keep Up With Regulatory Intelligence Systems Monitoring appeared first on PPD.

Clinical Trials 52

Clinical Trials Regulations Compliance Production 52

PPD

OCTOBER 21, 2024

Our white paper on the topic examines reasons biotech companies use the functional service provider (FSP) model to support their clinical development activities and the value that FSP engagements bring to these organizations.

International 52

International Clinical Development Clinical Trials Clinical Research 52

Fierce BioTech

JUNE 1, 2023

Download the white paper to learn more about the diagnostic potential of antibodies. Download the white paper to learn more about the diagnostic potential of antibodies. Autoantibodies: Powerful Biomarkers in Cancer Precision Medicine Autoantibodies hold great diagnostic potential for early cancer detection.

Treatment 52

Treatment Production Research 52

Advarra

MAY 26, 2023

The Association of American Cancer Institutes (AACI) recently published a white paper titled Collaboration to Develop Recommendations to Improve Trial Activation Timelines. The task force focused on three main areas of study activation: contract negotiation, budget development, and trial start up committee reviews.

Clinical Research 52

Clinical Research Trials Clinical Trials Research 52

Conversations in Drug Development Trends

FEBRUARY 21, 2024

We recently published a white paper discussing the value of proactive AME studies, best practices, and lessons we’ve learned over the years to help optimize your study. At Worldwide, our early phase team has conducted these studies for over 20 years, gaining invaluable experience and insights into best practices for an AME study.

Clinical Trials 80

Clinical Trials Pharmacy Clinical Pharmacology FDA 80

PPD

OCTOBER 2, 2024

A recent white paper from the PPD™ clinical research business of Thermo Fisher Scientific details how these functions have evolved over the years, moving from capabilities that were previously built up and maintained in-house, to the multiple outsourcing models available today.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Trials 52

sptlabtech

OCTOBER 31, 2024

By continuously listening to and incorporating user feedback, we make sure that firefly meets the evolving needs of researchers, helping you to work more efficiently and focus on what truly matters - delivering impactful results. supports compliance with 21 CFR Part 11, check out our white paper.

Compliance 59

Compliance Engineering Production Regulations 59

Conversations in Drug Development Trends

MARCH 1, 2024

To help determine if a master protocol could be a good fit for your study, check out this white paper for a more comprehensive overview of the appropriateness of master protocols in different contexts. Here are some relevant factors below: What Are the Advantages of a Master Protocol? Contact us.

Trials 78

Trials Disease Drug Development Clinical Trials 78

Conversations in Drug Development Trends

APRIL 4, 2024

Understanding and implementing the ICH M10 guidelines is not just a regulatory requirement; it’s a step towards more efficient and effective pharmaceutical research. To take a deeper dive into these guidelines, read our Q&A white paper , where industry-leading experts answer some common questions on bioanalytical guidance.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals International 80

EG Life Sciences

FEBRUARY 15, 2023

Every year, the FDA’s Center for Drug Evaluation and Research (CDER) clarifies to drug developers required study design elements, as well as other data needed on the drug application to support a full and comprehensive assessment. The year 2022 reflected a transformative path for the drug development industry.

Drug Development 52

Drug Development FDA Approval Drugs Virus 52

PPD

JULY 16, 2024

Our recent white paper explores the many ways in which a functional service provider (FSP) engagement delivers key pharmacovigilance (PV) capabilities necessary across the product life span and across different geographical regions. This research ultimately influenced the creation of a new submission process for the client.

Compliance 52

Compliance Regulations Production International 52

Broad Institute

NOVEMBER 4, 2024

Related news Novo Nordisk Foundation and Broad Institute of MIT and Harvard launch new research center for genomic mechanisms of disease Like many research endeavors, the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease at the Broad Institute of MIT and Harvard (NNFC) grew out of a conversation between scientists.

Disease 72

Disease Research Science International 72

PPD

OCTOBER 12, 2023

Emerging areas of pharmaceutical research not only bring novel opportunities but also new regulatory guidance. DOWNLOAD OUR WHITE PAPER Learn more about how PPD® Laboratory services can enhance your CGT projects. The post Informed Design of Bioanalytical PCR Assay Testing Parameters appeared first on PPD Inc.

Laboratories 52

Laboratories Protein Expression Clinical Trials Pharmacokinetics 52

Conversations in Drug Development Trends

MARCH 7, 2024

Are there differential financial incentives to encourage sponsors to initiate early phase clinical research under a CTA, and how do those incentives compare to incentives that exist to initiate the same research under an IND? For additional insights, download our full white paper, “ First-in-Human Studies: IND or CTA? ”.

Clinical Trials 52

Clinical Trials Trials FDA Drug Development 52

Conversations in Drug Development Trends

MARCH 1, 2023

The advent of outsourcing in clinical research came about in the 1980s based on transactional business-to-business interactions, which focused on the completion of specific development tasks. See how to unlock the full power of your CRO partner in our white paper, Optimal Outcomes in Clinical Research and Product Development.

Clinical Research 52

Clinical Research Clinical Trials Science Trials 52

Conversations in Drug Development Trends

AUGUST 14, 2024

Recent Advancements in Biomarker Research The latest advancements in biomarker research have further elevated the biomarker’s role in disease diagnosis, treatment, and monitoring. Check out our white paper to learn more about our services, or contact our team to find out how we can help support your oncology drug development program.

Treatment 78

Treatment Therapies Disease Protein Expression 78

Conversations in Drug Development Trends

MARCH 20, 2024

To learn more about these various genes and how they can affect your clinical trial participants, as well as to understand the full extent of the power of pharmacogenomics, check out our white paper. The post How Pharmacogenomics Can Benefit Your Clinical Trial appeared first on Worldwide Clinical Trials.

Clinical Trials 52

Clinical Trials Trials Treatment Compliance 52

PPD

DECEMBER 19, 2023

According to industry figures, the use of FSP models grew from 28% to 41% in just three years (2018-2021); by 2022, our internal research shows that nearly two-thirds of outsourcing budgets were allocated to FSP or hybrid FSP/FSO models. Read our white paper to learn the keys to successfully implementing functional service partnerships.

International 52

International Research Drug Development Pharmaceuticals 52

PPD

AUGUST 28, 2024

Researchers often employ cell therapy studies for oncology indications, and the U.S. A seasoned provider of contract research organization (CRO) solutions will infuse hybrid and decentralized solutions into studies, with experts that provide the breadth and depth of experience required to deploy mobile sites, wearables and more.

Trials 64

Trials Clinical Trials Therapies Drug Development 64

Conversations in Drug Development Trends

NOVEMBER 21, 2023

We thought, thousands of drugs haven’t been researched for thousands of other indications, so how can we disrupt the model? Dr. Fajgenbaum was determined to live, so he set out to leverage his limited medical training, scouring existing research literature and studying his body to find a treatment.

Disease 78

Disease Treatment Clinical Trials Clinical Development 78

PerkinElmer

FEBRUARY 18, 2021

A PerkinElmer White Paper offers a detailed look at the findings. These simple, stable compounds, used to treat various conditions, are the focus for 78% of preclinical research. For the minority of companies working with large molecules and biologics, most said they were in a phase of clinical research.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52

The Pharma Data

SEPTEMBER 11, 2020

Covid-19 command center aims to accelerate clinical research by individual sponsors to combat disease. The Covid-19 command center was created to provide sponsors of clinical trials pursuing in-house Covid-19 research with an AI-powered data analytics platform. Saama Technologies, Inc. ,

Clinical Trials 52

Clinical Trials Pharma Companies Trials Hospitals 52

PPD

JUNE 17, 2024

Each model delivers a distinct set of capabilities to the study sponsor: In an FSP arrangement, the contract research organization (CRO) performs a specific function or multiple functions (clinical operations, pharmacovigilance, etc.) Download our white paper The post The Power of Bespoke Hybrid FSP/FSO Solutions appeared first on PPD.

Clinical Trials 52

Clinical Trials Clinical Development Trials International 52

H1 Blog

NOVEMBER 15, 2023

For more information on how to build effective and compliant engagement plans, download our white paper: How AI Can Save Medical Affairs from Drowning in Data. The planning and execution of a KOL engagement strategy can be a complex process, with numerous considerations for compliance.

Compliance 59

Compliance Science Regulations Pharmaceutical Companies 59

PPD

MARCH 21, 2024

Partnering with a contract research organization (CRO) that has deep experience in pediatric clinical trials enables drug developers to successfully implement these strategies, which also have the potential to enhance study startup time, ease the burden on pediatric patients and their caregivers, and ultimately improve retention rates.

Clinical Trials 52

Clinical Trials Trials Drug Development Treatment 52

The Pharma Data

MARCH 31, 2022

™, Janssen seeks to elevate PAD research, collaboration, education and screening for communities placed at increased risk of cardiovascular disease. ™ has three main areas of focus: driving research, collaborating with powerful partners, and empowering individuals and communities. Through Save Legs. Change Lives. Change Lives.™

Disease 52

Disease Pharmaceutical Companies Pharmaceuticals Research 52

The Pharma Data

OCTOBER 16, 2020

This week’s round up features a digital solution for adapting clinical trials to ease the burden on the clinical research industry and an in vitro model that mimics the human airway epithelium using a newly developed technology platform. BetterLife conducts patient centric study via a fully remote clinical trial. Source link.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

The Pharma Data

MARCH 20, 2021

Other times, it’s necessary to brainstorm on the best topic by researching the audience’s key interests and concerns and how they fit with your objectives, so that you’re sure you have their best interests first and foremost. Then you need to (if you haven’t already!) For example, for awareness building, an infographic may be chosen.

Marketing 52

Marketing Production International Science 52

Agency IQ

JULY 8, 2024

The EPA stated that for fungal pathogens, current research indicates that some antifungal pesticides may lead to resistant organisms that pose a threat to human and animal health. The EPA notes that it is unable to quantify the percentage of U.S.-based based fungal infections that come from antimicrobial resistant fungi.

Virus 40

Virus Production Regulations FDA 40

The Pharma Data

JULY 28, 2021

On behalf of clients, MGA conducts original data analysis, constructs economic models, conducts research, writes white papers and expert reports and offers strategic advice. Drawing on years of policy experience, the MGA team uses analytics to help identify, quantify and solve economic policy problems. Source link: [link].

Marketing 52

Marketing Biosimilars Pharmaceuticals Drugs 52